UNIVERSITY OF CALIFORNIA SAN DIEGO

The progressive supranuclear palsy (PSP) market is experiencing significant growth driven by emerging therapies including AZP2006 and AMX0035, which are advancing through clinical trials with promising results.

A new therapy called "regulation of cues" combined with behavioral weight loss reduced veterans' risk of binge eating by 20% compared to standard cognitive-behavioral therapy in a randomized controlled trial.

A first-of-its-kind fluorescent drug called bevonescein successfully highlighted nerve tissue during surgery in a Phase 1-2 trial involving 27 cancer patients undergoing head and neck procedures.

Clinical review pharmacists at The US Oncology Network identified 1,271 cost-saving interventions across 5,600 patients, with 1,180 accepted interventions generating nearly $9 million in total cost of care reductions.

Researchers at the 2025 ASCO Annual Meeting revealed how the tumor microenvironment's complex balance of pro-tumor and anti-tumor immune forces can be manipulated to improve immunotherapy responses.

Semaglutide treatment slowed biological aging by approximately 9% and reduced epigenetic aging mortality risk by three years in HIV patients with lipohypertrophy over 32 weeks.

• Real-world data presented at AUA 2025 shows the CVAC System achieves significant kidney stone volume reduction of up to 99% in most patients, with one study reporting a median clearance rate of 96.4%. • The CVAC System demonstrated superior performance compared to flexible and navigable ureteric access sheath (FANS), removing significantly more absolute stone volume while maintaining consistently low intrarenal pressure. • Multiple studies using Quantitative Stone Analysis Software (QSAS) validate stone volume as a more precise and clinically meaningful measure for assessing kidney stone treatment outcomes.

Immorta Bio's SenoVax, a first-in-class senolytic immunotherapy, demonstrated regression of brain, lung, skin, pancreas, and breast cancers in animal models by targeting senescent cells that protect tumors from immune attack.

Researchers have identified a promising combination therapy using FAK inhibitors with RAF-MEK clamps that effectively overcomes treatment resistance in BRAF V600E-mutated melanoma.

Phase 4 PASSAGE study demonstrates tezepelumab reduced annualized asthma exacerbation rates by 79% in real-world patients with severe asthma after 6 months of treatment.